DK1411970T3 - Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia - Google Patents

Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia

Info

Publication number
DK1411970T3
DK1411970T3 DK01995681T DK01995681T DK1411970T3 DK 1411970 T3 DK1411970 T3 DK 1411970T3 DK 01995681 T DK01995681 T DK 01995681T DK 01995681 T DK01995681 T DK 01995681T DK 1411970 T3 DK1411970 T3 DK 1411970T3
Authority
DK
Denmark
Prior art keywords
sarp
scleroderma
prevention
treatment
medicament
Prior art date
Application number
DK01995681T
Other languages
Danish (da)
English (en)
Inventor
Christine Power
Jacques Colinge
Christine Plater-Zyberk
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of DK1411970T3 publication Critical patent/DK1411970T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DK01995681T 2000-12-06 2001-11-30 Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia DK1411970T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (fr) 2000-12-06 2001-11-30 Utilisation de sarp-1 dans le traitement et/ou la prevention de la sclerodermie

Publications (1)

Publication Number Publication Date
DK1411970T3 true DK1411970T3 (da) 2007-06-04

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01995681T DK1411970T3 (da) 2000-12-06 2001-11-30 Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia

Country Status (30)

Country Link
US (2) US7341995B2 (fr)
EP (2) EP1806144A3 (fr)
JP (1) JP2004525869A (fr)
KR (1) KR100804885B1 (fr)
CN (1) CN1323716C (fr)
AT (1) ATE359808T1 (fr)
AU (2) AU2636602A (fr)
BG (1) BG107941A (fr)
BR (1) BR0115983A (fr)
CA (1) CA2428092A1 (fr)
CY (1) CY1107687T1 (fr)
CZ (1) CZ20031855A3 (fr)
DE (1) DE60128009T2 (fr)
DK (1) DK1411970T3 (fr)
EA (1) EA005973B1 (fr)
EE (1) EE200300213A (fr)
ES (1) ES2281463T3 (fr)
HK (1) HK1068106A1 (fr)
HR (1) HRP20030426A2 (fr)
HU (1) HUP0302738A3 (fr)
IL (1) IL156069A0 (fr)
MX (1) MXPA03005027A (fr)
NO (1) NO20032597D0 (fr)
NZ (1) NZ525774A (fr)
PL (1) PL365316A1 (fr)
PT (1) PT1411970E (fr)
SK (1) SK8472003A3 (fr)
UA (1) UA83790C2 (fr)
WO (1) WO2002046225A2 (fr)
YU (1) YU45103A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US7638480B2 (en) 2002-04-10 2009-12-29 Laboratoires Serono Sa Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
CA2597098C (fr) 2005-02-08 2016-08-02 Steven R. Ledbetter Anticorps anti-tgf-beta
US7893018B2 (en) 2005-11-08 2011-02-22 Foundation For Biomedical Research And Innovation Method of treatment for ischemic heart disease
WO2009074637A1 (fr) * 2007-12-13 2009-06-18 Merck Serono S.A. Protéines de fusion sarp-1 et leurs utilisations
US20140148473A1 (en) * 2011-03-11 2014-05-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6433155B1 (en) * 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
US7026445B2 (en) * 1997-02-06 2006-04-11 Genetics Institute, Llc Human SDF-5 protein and compositions
SK287491B6 (sk) * 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Fúzne proteíny interferónu- beta-1a a ich použitie

Also Published As

Publication number Publication date
CN1553806A (zh) 2004-12-08
MXPA03005027A (es) 2003-09-05
IL156069A0 (en) 2003-12-23
ES2281463T3 (es) 2007-10-01
EE200300213A (et) 2003-08-15
EA200300639A1 (ru) 2003-12-25
SK8472003A3 (en) 2003-10-07
BG107941A (bg) 2004-01-30
CN1323716C (zh) 2007-07-04
DE60128009T2 (de) 2007-08-23
HK1068106A1 (en) 2005-04-22
EP1806144A3 (fr) 2008-04-23
US7655628B2 (en) 2010-02-02
KR100804885B1 (ko) 2008-02-20
EP1806144A2 (fr) 2007-07-11
KR20030076585A (ko) 2003-09-26
AU2002226366B2 (en) 2007-03-22
HUP0302738A3 (en) 2010-01-28
EP1411970A2 (fr) 2004-04-28
US7341995B2 (en) 2008-03-11
YU45103A (sh) 2006-08-17
PT1411970E (pt) 2007-05-31
EP1411970B1 (fr) 2007-04-18
JP2004525869A (ja) 2004-08-26
ATE359808T1 (de) 2007-05-15
US20080107627A1 (en) 2008-05-08
CA2428092A1 (fr) 2002-06-13
HUP0302738A2 (hu) 2003-11-28
US20050113291A1 (en) 2005-05-26
CY1107687T1 (el) 2012-05-23
EA005973B1 (ru) 2005-08-25
DE60128009D1 (de) 2007-05-31
WO2002046225A3 (fr) 2004-01-08
NO20032597L (no) 2003-06-06
CZ20031855A3 (cs) 2003-09-17
NZ525774A (en) 2006-03-31
WO2002046225A2 (fr) 2002-06-13
PL365316A1 (en) 2004-12-27
NO20032597D0 (no) 2003-06-06
HRP20030426A2 (en) 2005-04-30
BR0115983A (pt) 2003-12-30
AU2636602A (en) 2002-06-18
UA83790C2 (ru) 2008-08-26

Similar Documents

Publication Publication Date Title
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
SE0102315D0 (sv) Compounds
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DK1401806T3 (da) Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
DE60105953D1 (de) Sicherheitsspritze
EE05020B1 (et) Glburiidi ravimkoostis
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
DK1411917T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bevægelsesforstyrrelser
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
DK1326599T3 (da) Anvendelse af aivlosin til behandling eller forebyggelse af Lawsonia-infektioner i grise
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
ATE391489T1 (de) Haarbehandlungszusammensetzungen
EE200200693A (et) Interferoon hulgiskleroosi raviks
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
DE60127224D1 (de) Sicherheitsspritze
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
DE60034770D1 (de) Stabile fumagillin-formulierung
CL2004001005A1 (es) Compuestos derivados de macrolidos de 15 miembros, sustituidos en posicion 4", procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topicas.
AR028458A1 (es) Un estuche de combinacion usado en el tratamiento del paludismo
DK1313489T3 (da) Farmaceutiske sammensætninger til behandling af mucositis, stomatitis og Behcet's syndrom
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.